Sutro Biopharma (STRO) — Capital Reinvestment Ratio
Latest as of June 2024:
0.08x
Sutro Biopharma (STRO) has a Capital Reinvestment Ratio of 0.08x as of June 2024, meaning it reinvests 0% of its operating cash flow ($9.46 Million) in capital expenditures ($756.00K). See STRO FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.08x
Capex / Operating Cash Flow
Operating Cash Flow
$9.46 Million
USD
Capital Expenditures
$756.00K
USD
Data as of
Jun 2024
Most recent filing
Sutro Biopharma Capital Reinvestment Ratio (2018–2022)
This chart tracks Sutro Biopharma's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for Sutro Biopharma (2018–2022)
Year-by-year Capital Reinvestment Ratio for Sutro Biopharma from 2018 to 2022. For live market cap and broader valuation context, see Sutro Biopharma (STRO) total market value.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2022 | 2.21x | $3.55 Million | $7.86 Million | ▲ +1703.6% |
| 2018 | 0.12x | $12.68 Million | $1.56 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow